Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Angelini Ventures has already invested €125 million in 22 startups
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated